Pharma Deals Review, Vol 2004, No 50 (2004)

Font Size:  Small  Medium  Large

Vernalis Licenses its Lead Compound for Parkinson’s disease to Biogen Idec

Business Review Editor

Abstract


Vernalis entered into an exclusive worldwide licensing deal with Biogen to develop and commercialise its lead compound V2006 for treating Parkinson’s disease and other CNS disorders. The deal is potentially worth up to US$100 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.